Shuttle Pharmaceuticals Holdings, Inc. (SHPH) intrinsic value & 10-year financials
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $5.08
- Market cap
- $8.3M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -908.2%
- Free cash flow (FY2025)
- —
SHPH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$11.7M | -$7.16 | — | — | -2126.4% |
| FY2024 | — | -$9.1M | -$3.30 | — | — | -2256.4% |
| FY2023 | — | -$6.6M | -$0.44 | -$5.6M | — | -369.7% |
| FY2022 | — | -$3.0M | -$0.29 | — | — | 153.0% |
| FY2021 | — | -$1.2M | — | — | — | 58.2% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Shuttle Pharmaceuticals Holdings, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Shuttle Pharmaceuticals Holdings, Inc. has historically struggled to out-earn its cost of capital, averaging just 2.4% ROIC.
Shuttle Pharmaceuticals Holdings, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Shuttle Pharmaceuticals Holdings, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.